CG Oncology, Inc. Common stock (CGON) is a Healthcare · Biotechnology company listed on NASDAQ. Price $73.47 (-2.84%), Market cap $6.13B, 52-week low–high $23.95 ~ $74.00.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent;
Financial statements, price targets, institutional (13F) holdings and related news for CG Oncology, Inc. Common stock are updated in real time on BlackAll Trade.
CG Oncology, Inc. Common stock trades at $73.47 (-2.84%). Real-time quotes and charts are available on BlackAll Trade.
CG Oncology, Inc. Common stock has a market cap of about $6.13B.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's prod